BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Smeets MJR, Liem RSL. No Uniformity in the References of Clinical Practice Guidelines for Bariatric Surgery: a Review of 3 Similar Guidelines Published in 2020. Obes Surg 2021;31:5427-40. [PMID: 34655055 DOI: 10.1007/s11695-021-05746-7] [Reference Citation Analysis]
2 Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
3 Sun H, Liu Y, Zhang Y, Jie Y, Wu Y, Li Z, Wei X, Li X, Niu B. Finite versus Indefinite Nucleos(t)ide Analogue Therapy of Patients with Chronic Hepatitis B Exhibiting Negative HBsAg Levels after Treatment. BioMed Research International 2022;2022:1-10. [DOI: 10.1155/2022/6069781] [Reference Citation Analysis]
4 Lee HA, Lee HW, Park Y, Kim HS, Seo YS. Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients. J Clin Med 2022;11:1729. [PMID: 35330053 DOI: 10.3390/jcm11061729] [Reference Citation Analysis]
5 Lee JS, Lee HW, Lim TS, Min IK, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. Cancers 2022;14:711. [DOI: 10.3390/cancers14030711] [Reference Citation Analysis]
6 Lee H, Jang S, Ahn SH, Kim BK. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL. Hepatol Int 2022. [PMID: 35322374 DOI: 10.1007/s12072-022-10310-1] [Reference Citation Analysis]
7 Chun HS, Park S, Lee M, Cho Y, Kim HS, Choe AR, Kim HY, Yoo K, Kim TH. Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:3424. [PMID: 34298640 DOI: 10.3390/cancers13143424] [Reference Citation Analysis]
8 Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2021. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Reference Citation Analysis]
10 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
11 Lee YS, Bang SM, Lee YS. Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. J Clin Med 2021;10:2320. [PMID: 34073357 DOI: 10.3390/jcm10112320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim DS, Park SY, Kim BK, Park JY, Kim DY, Han KH, Lee YR, Tak WY, Kweon YO, Jung I, Han M, Kim EH, Ahn SH, Kim SU. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. J Korean Med Sci 2021;36:e105. [PMID: 33904261 DOI: 10.3346/jkms.2021.36.e105] [Reference Citation Analysis]
13 Shin S, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. Diagnostics 2022;12:441. [DOI: 10.3390/diagnostics12020441] [Reference Citation Analysis]
14 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
15 Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med 2022:S0953-6205(22)00252-7. [PMID: 35835625 DOI: 10.1016/j.ejim.2022.07.003] [Reference Citation Analysis]
16 Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. Hepatol Commun 2022. [PMID: 35766457 DOI: 10.1002/hep4.2022] [Reference Citation Analysis]
17 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021; 27(26): 4004-4017 [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Choi J, Lim YS. Secondary prevention of hepatitis B virus-related hepatocellular carcinoma with current antiviral therapies. Kaohsiung J Med Sci 2021;37:262-7. [PMID: 33502828 DOI: 10.1002/kjm2.12364] [Reference Citation Analysis]
19 Kang B, Yi DY, Choe B. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries. Front Pediatr 2022;9:809838. [DOI: 10.3389/fped.2021.809838] [Reference Citation Analysis]
20 Zhong Z, Liao W, Dai L, Feng X, Su G, Gao Y, Wu Q, Yang P. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis 2021:annrheumdis-2021-221650. [PMID: 34933869 DOI: 10.1136/annrheumdis-2021-221650] [Reference Citation Analysis]
21 Lim J, Lee JB, An J, Song GW, Kim KM, Lee HC, Shim JH. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study. J Viral Hepat 2022. [PMID: 35718999 DOI: 10.1111/jvh.13721] [Reference Citation Analysis]
22 Chon HY, Ahn SH, Kim YJ, Yoon JH, Lee JH, Sinn DH, Kim SU. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int 2021;15:1328-36. [PMID: 34799838 DOI: 10.1007/s12072-021-10262-y] [Reference Citation Analysis]
23 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;28:1570-8. [PMID: 34435412 DOI: 10.1111/jvh.13601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;15:1083-92. [PMID: 34402025 DOI: 10.1007/s12072-021-10234-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
25 Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Reference Citation Analysis]
26 Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Reference Citation Analysis]
27 Alpsoy A, Adanir H, Bayramoglu Z, Elpek GO. Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study. World J Hepatol 2022; 14(1): 260-273 [DOI: 10.4254/wjh.v14.i1.260] [Reference Citation Analysis]